☆ 3.8 Article

Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection

PNAS NEXUS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Samuel M. S. Cheng et al.

Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Hung Fu Tseng et al.

Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.

NATURE MEDICINE (2022)

添加到收藏夹

Letter Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Shirley Collie et al.

Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients

Hagai Ligumsky et al.

Summary: The study found that solid tumor patients had lower antibody titers and a lower proportion of seropositive patients compared to healthy individuals, especially among chemotherapy-treated patients. The BNT162b2 vaccine was safe and well-tolerated in these patients, with no severe side effects reported. Continued use of personal protective measures is recommended for this population even after vaccination.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Laurence Chu et al.

Summary: The results of the study demonstrate that a booster dose of mRNA-1273 administered more than 6 months after the primary vaccination series is safe and leads to significantly higher levels of neutralizing antibodies, potentially increasing vaccine effectiveness against SARS-CoV-2 infection and disease.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records

Michiel J. M. Niesen et al.

Summary: This study evaluated the safety of the third dose of FDA-approved COVID-19 mRNA vaccines. The findings suggest that although the third dose is associated with an increased reporting of low-severity adverse events, the risk of severe adverse events remains comparable to the standard two-dose regime. This study provides evidence for the safety of third vaccination doses in eligible individuals for booster vaccination.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection

Arjun Puranik et al.

Summary: The mRNA-1273 and BNT162b2 vaccines provide strong protection against symptomatic SARS-CoV-2 infection. However, their effectiveness was reduced during July-September and mRNA-1273 had a lower risk of breakthrough infection compared to BNT162b2.

MED (2022)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz et al.

Summary: This study focuses on evaluating the anti-S IgG antibody levels before and after the administration of a third dose of the BNT162b2 vaccine in individuals aged 60 and older in Israel.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Protection against Covid-19 by BNT162b2 Booster across Age Groups

Yinon M. Bar-On et al.

Summary: The study shows that receiving a booster dose of the BNT162b2 vaccine can significantly lower the rates of confirmed Covid-19 and severe illness, as well as reduce mortality among individuals aged 60 and above.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Ronen Arbel et al.

Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study

Ariel Israel et al.

Summary: In this study, it was found that the risk of COVID-19 infection gradually increased in adults who received their second dose of the BNT162b2 mRNA vaccine after at least 90 days, based on electronic health records.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

Katia J. Bruxvoort et al.

Summary: The study evaluated the effectiveness of mRNA-1273 vaccine against SARS-CoV-2 variants, especially the delta variant, by time since vaccination. Two doses of the vaccine showed high effectiveness against all variants, with a decline in effectiveness against delta variant over time. One dose of the vaccine also demonstrated moderate effectiveness against delta infection.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Angela Choi et al.

Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

M. G. Thompson et al.

Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

Shaun J. Grannis et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Immunology

Intraseason Waning of Influenza Vaccine Effectiveness

G. Thomas Ray et al.

CLINICAL INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness

Sheena G. Sullivan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)

添加到收藏夹

Article Health Care Sciences & Services

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

HD Quan et al.

MEDICAL CARE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.